Coya Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Coya Therapeutics, Inc. filed a Current Report on Form 8-K reporting the results of its Annual Meeting of Stockholders held on June 28, 2023. The report was signed and dated June 29, 2023. Coya is a Delaware corporation whose common stock trades on Nasdaq under the symbol COYA.
Financial and Operating Metrics
This filing does not provide revenue, profitability, cash flow, margin, debt, liquidity, or other operating-financial metrics.
Material Matters and Voting Results
- Director election: Hideki Garren, M.D., Ph.D. was elected as a Class I director for a three-year term, subject to earlier termination or replacement.
- Votes: 3,414,906 for, 405,471 withheld, and 221,601 broker non-votes.
- Auditor ratification: Stockholders approved the appointment of Weaver and Tidwell, L.L.P. as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Auditor votes: 4,008,651 for, 31,504 against, and 1,823 abstentions.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, outlook, management commentary, contingencies, or unusual financial items. It identifies the company as an emerging growth company.
Investor Verification Items
- Verify the elected director’s continued service, committee assignments, and term details.
- Review the company’s subsequent filings for any changes involving Weaver and Tidwell, L.L.P. or the company’s independent auditor.
- Consult the company’s periodic reports for financial results, liquidity, financing needs, and clinical or business developments, which are not addressed in this filing.